Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 1
2001 1
2002 1
2003 3
2004 4
2005 4
2006 4
2007 8
2008 11
2009 16
2010 12
2011 15
2012 20
2013 19
2014 13
2015 15
2016 13
2017 13
2018 16
2019 7
2020 9
2021 20
2022 6
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

224 results

Results by year

Filters applied: . Clear all
Page 1
Modeling Viral Spread.
Graw F, Perelson AS. Graw F, et al. Annu Rev Virol. 2016 Sep 29;3(1):555-572. doi: 10.1146/annurev-virology-110615-042249. Epub 2016 Aug 31. Annu Rev Virol. 2016. PMID: 27618637 Free PMC article. Review.
The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy.
McMyn NF, Varriale J, Fray EJ, Zitzmann C, MacLeod H, Lai J, Singhal A, Moskovljevic M, Garcia MA, Lopez BM, Hariharan V, Rhodehouse K, Lynn K, Tebas P, Mounzer K, Montaner LJ, Benko E, Kovacs C, Hoh R, Simonetti FR, Laird GM, Deeks SG, Ribeiro RM, Perelson AS, Siliciano RF, Siliciano JM. McMyn NF, et al. J Clin Invest. 2023 Sep 1;133(17):e171554. doi: 10.1172/JCI171554. J Clin Invest. 2023. PMID: 37463049 Free PMC article.
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, Monczor AN, Lupo S, Gelderblom HC, Ansel JL, Kanjilal DG, Maxfield LF, Nkolola J, Borducchi EN, Abbink P, Liu J, Peter L, Chandrashekar A, Nityanandam R, Lin Z, Setaro A, Sapiente J, Chen Z, Sunner L, Cassidy T, Bennett C, Sato A, Mayer B, Perelson AS, deCamp A, Priddy FH, Wagh K, Giorgi EE, Yates NL, Arduino RC, DeJesus E, Tomaras GD, Seaman MS, Korber B, Barouch DH. Stephenson KE, et al. Nat Med. 2021 Oct;27(10):1718-1724. doi: 10.1038/s41591-021-01509-0. Epub 2021 Oct 7. Nat Med. 2021. PMID: 34621054 Free PMC article. Clinical Trial.
AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques.
Dashti A, Sukkestad S, Horner AM, Neja M, Siddiqi Z, Waller C, Goldy J, Monroe D, Lin A, Schoof N, Singh V, Mavigner M, Lifson JD, Deleage C, Tuyishime M, Falcinelli SD, King HAD, Ke R, Mason RD, Archin NM, Dunham RM, Safrit JT, Jean S, Perelson AS, Margolis DM, Ferrari G, Roederer M, Silvestri G, Chahroudi A. Dashti A, et al. Nat Med. 2023 Oct;29(10):2535-2546. doi: 10.1038/s41591-023-02570-7. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783968 Free PMC article.
Viral kinetic modeling: state of the art.
Canini L, Perelson AS. Canini L, et al. J Pharmacokinet Pharmacodyn. 2014 Oct;41(5):431-43. doi: 10.1007/s10928-014-9363-3. Epub 2014 Jun 25. J Pharmacokinet Pharmacodyn. 2014. PMID: 24961742 Free PMC article. Review.
Modelling hepatitis C therapy--predicting effects of treatment.
Perelson AS, Guedj J. Perelson AS, et al. Nat Rev Gastroenterol Hepatol. 2015 Aug;12(8):437-45. doi: 10.1038/nrgastro.2015.97. Epub 2015 Jun 30. Nat Rev Gastroenterol Hepatol. 2015. PMID: 26122475 Free PMC article. Review.
224 results